Type 2 diabetes and bone fractures

Current Opinion in Endocrinology, Diabetes and Obesity

Volumn 19, Issue 2, 2012, Pages 128-135

  Moseley, Kendall F ^a  

^a JOHNS HOPKINS BAYVIEW MEDICAL CENTER   (United States)

Author keywords

bone mineral density; fracture; mesenchymal stem cell; type 2 diabetes mellitus

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ADVANCED GLYCATION END PRODUCT; REACTIVE OXYGEN METABOLITE; SEROTONIN UPTAKE INHIBITOR;

AUTONOMIC DYSFUNCTION; BODY COMPOSITION; BONE DENSITY; BONE DEVELOPMENT; BONE FRAGILITY; BONE MARROW; BONE METABOLISM; BONE REMODELING; BONE STRENGTH; CELL DIFFERENTIATION; DIABETIC RETINOPATHY; DISEASE ASSOCIATION; FALL RISK; FAT BODY; FRACTURE; HIGH RISK PATIENT; HUMAN; INSULIN SENSITIVITY; KIDNEY DISEASE; LEAN BODY WEIGHT; MESENCHYMAL STEM CELL; MICROENVIRONMENT; NON INSULIN DEPENDENT DIABETES MELLITUS; OSTEOBLAST; RENAL OSTEODYSTROPHY; REVIEW; RISK ASSESSMENT;

ACCIDENTAL FALLS; ADULT; AGED; AGED, 80 AND OVER; AUTONOMIC NERVOUS SYSTEM DISEASES; BODY MASS INDEX; BONE DENSITY; BONE REMODELING; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; FEMALE; FRACTURES, BONE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; RENAL OSTEODYSTROPHY; RISK FACTORS; THIAZOLIDINEDIONES;

EID: 84858278694     PISSN: 1752296X     EISSN: 17522978     Source Type: Journal    
DOI: 10.1097/MED.0b013e328350a6e1     Document Type: Review

References (110)

1. Dawson-Hughes B, Tosteson AN, Melton LJ 3rd, et al. Implications of absolute fracture risk assessment for osteoporosis practice guidelines in the USA. Osteoporos Int 2008; 19:449-458.
2. Looker AC, Dawson-Hughes B, Tosteson AN, et al. Hip fracture risk in older US adults by treatment eligibility status based on new National Osteoporosis Foundation guidance. Osteoporos Int 2010; 22:541-549. Updated guidelines based on the National Health and Nutrition Examination Survey II data demonstrating that men and women eligible for osteoporosis treatment are five times more likely to experience hip fracture.
3. Leibson CL, Tosteson AN, Gabriel SE, et al. Mortality, disability, and nursing home use for persons with and without hip fracture: a population-based study. J Am Geriatr Soc 2002; 50:1644-1650. (Pubitemid 35192535)
4. Tosteson AN, Gabriel SE, Grove MR, et al. Impact of hip and vertebral fractures on quality-adjusted life years. Osteoporos Int 2001; 12:1042-1049. (Pubitemid 34105976)
5. Arinzon Z, Fidelman Z, Zuta A, et al. Functional recovery after hip fracture in old-old elderly patients. Arch Gerontol Geriatr 2005; 40:327-336. (Pubitemid 40467567)
6. Gulcelik NE, Bayraktar M, Caglar O, et al. Mortality after hip fracture in diabetic patients. Exp Clin Endocrinol Diabetes 2011; 119:414-418. Men and women with T2DM are at an increased risk of mortality following hip fracture compared with those who do not have diabetes.
7. Melton LJ 3rd, Gabriel SE, Crowson CS, et al. Cost-equivalence of different osteoporotic fractures. Osteoporos Int 2003; 14:383-388. (Pubitemid 36919219)
8. Tosteson AN, Melton LJ 3rd, Dawson-Hughes B, et al. Cost-effective osteoporosis treatment thresholds: the United States perspective. Osteoporos Int 2008; 19:437-447.
9. Dawson-Hughes B, Looker AC, Tosteson AN, et al. The potential impact of new National Osteoporosis Foundation guidance on treatment patterns. Osteoporos Int 2010; 21:41-52.
10. van Daele PL, Stolk RP, Burger H, et al. Bone density in noninsulin-dependent diabetes mellitus. The Rotterdam Study. Ann Intern Med 1995; 122:409-414.
11. Rakic V, Davis WA, Chubb SA, et al. Bone mineral density and its determinants in diabetes: the Fremantle Diabetes Study. Diabetologia 2006; 49:863-871.
12. De Laet C, Kanis JA, Oden A, et al. Body mass index as a predictor of fracture risk: a meta-analysis. Osteoporos Int 2005; 16:1330-1338. (Pubitemid 41532085)
13. Ooms ME, Lips P, Van Lingen A, et al. Determinants of bone mineral density and risk factors for osteoporosis in healthy elderly women. J Bone Miner Res 1993; 8:669-675. (Pubitemid 23157790)
14. Duan Y, Beck TJ, Wang XF, et al. Structural and biomechanical basis of sexual dimorphism in femoral neck fragility has its origins in growth and aging. J Bone Miner Res 2003; 18:1766-1774. (Pubitemid 37322553)
15. Beck TJ, Oreskovic TL, Stone KL, et al. Structural adaptation to changing skeletal load in the progression toward hip fragility: the study of osteoporotic fractures. J Bone Miner Res 2001; 16:1108-1119. (Pubitemid 32467155)
16. Travison TG, Araujo AB, Esche GR, et al. Lean mass and not fat mass is associated with male proximal femur strength. J Bone Miner Res 2008; 23:189-198. (Pubitemid 351160032)
17. Barrett-Connor E, Kritz-Silverstein D. Does hyperinsulinemia preserve bone? Diabetes Care 1996; 19:1388-1392. (Pubitemid 26418620)
18. Thrailkill KM, Lumpkin CK Jr, Bunn RC, et al. Is insulin an anabolic agent in bone? Dissecting the diabetic bone for clues. Am J Physiol Endocrinol Metab 2005; 289:E735-E745. (Pubitemid 41504371)
19. Nyman JS, Even JL, Jo CH, et al. Increasing duration of type 1 diabetes perturbs the strength-structure relationship and increases brittleness of bone. Bone 2011; 48:733-740.
20. Botushanov NP, Orbetzova MM. Bone mineral density and fracture risk in patients with type 1 and type 2 diabetes mellitus. Folia Med (Plovdiv) 2009; 51:12-17.
21. Montagnani A, Gonnelli S, Alessandri M, et al. Osteoporosis and risk of fracture in patients with diabetes: an update. Aging Clin Exp Res 2011; 23:84-90.
22. Isidro ML, Ruano B. Bone disease in diabetes. Curr Diabetes Rev 2010; 6:144-155.
23. Schwartz AV, Sellmeyer DE. Diabetes, fracture, and bone fragility. Curr Osteoporos Rep 2007; 5:105-111. (Pubitemid 47571960)
24. de Liefde II, van der Klift M, de Laet CE, et al. Bone mineral density and fracture risk in type-2 diabetes mellitus: the Rotterdam Study. Osteoporos Int 2005; 16:1713-1720.
25. Schwartz AV, Sellmeyer DE, Ensrud KE, et al. Older women with diabetes have an increased risk of fracture: a prospective study. J Clin Endocrinol Metab 2001; 86:32-38. (Pubitemid 32109771)
26. Strotmeyer ES, Cauley JA, Schwartz AV, et al. Nontraumatic fracture risk with diabetes mellitus and impaired fasting glucose in older white and black adults: the health, aging, and body composition study. Arch Intern Med 2005; 165:1612-1617. (Pubitemid 41124155)
27. Janghorbani M, Feskanich D, Willett WC, et al. Prospective study of diabetes and risk of hip fracture: the Nurses' Health Study. Diabetes Care 2006; 29:1573-1578. (Pubitemid 44127583)
28. Schwartz AV, Sellmeyer DE, Vittinghoff E, et al. Thiazolidinedione use and bone loss in older diabetic adults. J Clin Endocrinol Metab 2006; 91:3349-3354. (Pubitemid 44402103)
29. Monami M, Cresci B, Colombini A, et al. Bone fractures and hypoglycemic treatment in type 2 diabetic patients: a case-control study. Diabetes Care 2008; 31:199-203. (Pubitemid 351213319)
30. Gruntmanis U, Fordan S, Ghayee HK, et al. The peroxisome proliferator-activated receptor-gamma agonist rosiglitazone increases bone resorption in women with type 2 diabetes: a randomized, controlled trial. Calcif Tissue Int 2010; 86:343-349. Double-blind, placebo-controlled, randomized trial showing that 6 months of rosiglitazone treatment in T2DM causes significant elevations in markers of bone resorption.
31. Grey A, Bolland M, Gamble G, et al. The peroxisome proliferator-activated receptor-gamma agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial. J Clin Endocrinol Metab 2007; 92:1305-1310. (Pubitemid 46556402)
32. Kahn SE, Zinman B, Lachin JM, et al. Rosiglitazone-associated fractures in type 2 diabetes: an Analysis from A Diabetes Outcome Progression Trial (ADOPT). Diabetes Care 2008; 31:845-851.
33. Meier C, Kraenzlin ME, Bodmer M, et al. Use of thiazolidinediones and fracture risk. Arch Intern Med 2008; 168:820-825. (Pubitemid 351620084)
34. Vestergaard P. Bone metabolism in type 2 diabetes and role of thiazolidinediones. Curr Opin Endocrinol Diabetes Obes 2009; 16:125-131.
35. Golden SH, Lazo M, Carnethon M, et al. Examining a bidirectional association between depressive symptoms and diabetes. JAMA 2008; 299:2751-2759. (Pubitemid 351846850)
36. Mezuk B, Eaton WW, Albrecht S, et al. Depression and type 2 diabetes over the lifespan: a meta-analysis. Diabetes Care 2008; 31:2383-2390.
37. Karsenty G, Gershon MD. The Importance of the Gastrointestinal Tract in the Control of Bone Mass Accrual. Gastroenterology 2011; 141:439-442.
38. Yadav VK, Oury F, Suda N, et al. A serotonin-dependent mechanism explains the leptin regulation of bone mass, appetite, and energy expenditure. Cell 2009; 138:976-989.
39. Karsenty G, Oury F. The central regulation of bone mass, the first link between bone remodeling and energy metabolism. J Clin Endocrinol Metab 2010; 95:4795-4801. Review highlighting the complex molecular pathways by which leptin mediates bone metabolism and appetite through brain signaling.
40. Diem SJ, Blackwell TL, Stone KL, et al. Use of antidepressants and rates of hip bone loss in older women: the study of osteoporotic fractures. Arch Intern Med 2007; 167:1240-1245. (Pubitemid 46998494)
41. Haney EM, Chan BK, Diem SJ, et al. Association of low bone mineral density with selective serotonin reuptake inhibitor use by older men. Arch Intern Med 2007; 167:1246-1251. (Pubitemid 46998495)
42. Williams LJ, Henry MJ, Berk M, et al. Selective serotonin reuptake inhibitor use and bone mineral density in women with a history of depression. Int Clin Psychopharmacol 2008; 23:84-87. (Pubitemid 351317280)
43. Richards JB, Papaioannou A, Adachi JD, et al. Effect of selective serotonin reuptake inhibitors on the risk of fracture. Arch Intern Med 2007; 167:188-194. (Pubitemid 46148067)
44. Lewis CE, Ewing SK, Taylor BC, et al. Predictors of nonspine fracture in elderly men: the MrOS study. J Bone Miner Res 2007; 22:211-219. (Pubitemid 46167791)
45. Goltzman D. LRP5, serotonin and bone: complexity, contradictions and conundrums. J Bone Miner Res 2011; 26:1997-2001. Summary of the hypothesized effects of serotonin on bone metabolism and key pathways involved in this gut-mediated process.
46. Viegas M, Costa C, Lopes A, et al. Prevalence of osteoporosis and vertebral fractures in postmenopausal women with type 2 diabetes mellitus and their relationship with duration of the disease and chronic complications. J Diabetes Complications 2011; 25:216-221. Duration of type 2 diabetes was strongly associated with prevalence of osteoporosis and vertebral fractures in women with T2DM, irrespective of glycemic control.
47. Schwartz AV, Vittinghoff E, Sellmeyer DE, et al. Diabetes-related complications, glycemic control, and falls in older adults. Diabetes Care 2008; 31:391-396.
48. McNair P, Christensen MS, Madsbad S, et al. Hypoparathyroidism in diabetes mellitus. Acta Endocrinol (Copenh) 1981; 96:81-86. (Pubitemid 11133842)
49. Oikawa A, Siragusa M, Quaini F, et al. Diabetes mellitus induces bone marrow microangiopathy. Arterioscler Thromb Vasc Biol 2010; 30:498-508. Bone marrow endothelial cells from mice with T1DM showed higher levels of oxidative stress, DNA damage and increased apoptosis. The marrow microenviromemt was significantly altered by systemic changes in T1DM.
50. Capla JM, Grogan RH, Callaghan MJ, et al. Diabetes impairs endothelial progenitor cell-mediated blood vessel formation in response to hypoxia. Plast Reconstr Surg 2007; 119:59-70. (Pubitemid 46360247)
51. Tanko LB, Bagger YZ, Christiansen C. Low bone mineral density in the hip as a marker of advanced atherosclerosis in elderly women. Calcif Tissue Int 2003; 73:15-20. (Pubitemid 37022074)
52. Vogt MT, Cauley JA, Kuller LH, et al. Bone mineral density and blood flow to the lower extremities: the study of osteoporotic fractures. J Bone Miner Res 1997; 12:283-289. (Pubitemid 27086311)
53. Jehle PM, Jehle DR, Mohan S, et al. Serum levels of insulin-like growth factor system components and relationship to bone metabolism in Type 1 and Type 2 diabetes mellitus patients. J Endocrinol 1998; 159:297-306. (Pubitemid 28520183)
54. Hock JM, Centrella M, Canalis E. Insulin-like growth factor I has independent effects on bone matrix formation and cell replication. Endocrinology 1988; 122:254-260. (Pubitemid 18027610)
55. Kanazawa I, Yamaguchi T, Sugimoto T. Serum insulin-like growth factor-I is a marker for assessing the severity of vertebral fractures in postmenopausal women with type 2 diabetes mellitus. Osteoporos Int 2011; 22:1191-1198. Serum levels of IGF-1 were inversely correlated with vertebral fractures in women with T2DM. IGF-1 may be useful as a marker of vertebral fracture severity.
56. van den Beld AW, de Jong FH, Grobbee DE, et al. Measures of bioavailable serum testosterone and estradiol and their relationships with muscle strength, bone density, and body composition in elderly men. J Clin Endocrinol Metab 2000; 85:3276-3282.
57. Kapoor D, Aldred H, Clark S, et al. Clinical and biochemical assessment of hypogonadism in men with type 2 diabetes: correlations with bioavailable testosterone and visceral adiposity. Diabetes Care 2007; 30:911-917. (Pubitemid 46556586)
58. Dhindsa S, Bhatia V, Dhindsa G, et al. The effects of hypogonadism on body composition and bone mineral density in type 2 diabetic patients. Diabetes Care 2007; 30:1860-1861. (Pubitemid 47036365)
59. Corona G, Monami M, Rastrelli G, et al. Type 2 diabetes mellitus and testosterone: a meta-analysis study. Int J Androl 2010; 34:528-540.
60. Baynes KC, Boucher BJ, Feskens EJ, et al. Vitamin D, glucose tolerance and insulinaemia in elderly men. Diabetologia 1997; 40:344-347. (Pubitemid 27096561)
61. Perry HM 3rd, Horowitz M, Morley JE, et al. Longitudinal changes in serum 25-hydroxyvitamin D in older people. Metabolism 1999, 48:1028-1032. (Pubitemid 29374922)
62. Pittas AG, Lau J, Hu FB, et al. The role of vitamin D and calcium in type 2 diabetes. A systematic review and meta-analysis. J Clin Endocrinol Metab 2007; 92:2017-2029. (Pubitemid 46997093)
63. Scragg R, Sowers M, Bell C, et al. Serum 25-hydroxyvitamin D, diabetes, and ethnicity in the Third National Health and Nutrition Examination Survey. Diabetes Care 2004; 27:2813-2818. (Pubitemid 39565042)
64. Aloia JF, Vaswani A, Ma R, et al. To what extent is bone mass determined by fat-free or fat mass? Am J Clin Nutr 1995; 61:1110-1114.
65. Pluijm SM, Visser M, Smit JH, et al. Determinants of bone mineral density in older men and women: body composition as mediator. J Bone Miner Res 2001; 16:2142-2151. (Pubitemid 32995407)
66. Visser M, Kiel DP, Langlois J, et al. Muscle mass and fat mass in relation to bone mineral density in very old men and women: the Framingham Heart Study. Appl Radiat Isot 1998; 49:745-747. (Pubitemid 28150111)
67. Stewart KJ, Deregis JR, Turner KL, et al. Fitness, fatness and activity as predictors of bone mineral density in older persons. J Intern Med 2002; 252:381-388. (Pubitemid 36706569)
68. Moseley KF, Dobrosieski DA, Stewart KJ, et al. Lean mass and fat mass predict bone mineral density in middle-aged individuals with noninsulin-requiring type 2 diabetes mellitus. Clin Endocrinol (Oxf) 2011; 74:565-571. First study describing the association between body composition and bone mineral density in men and women with uncomplicated, noninsulin-requiring T2DM.
69. Moseley KF, Dobrosielski DA, Stewart KJ, et al. Lean mass predicts hip geometry in men and women with noninsulin-requiring type 2 diabetes mellitus. J Clin Densitom 2011; 14:332-339. First published study describing the association between hip geometry and body composition in men and women with T2DM.
70. Kim TN, Park MS, Yang SJ, et al. Prevalence and determinant factors of sarcopenia in patients with type 2 diabetes: the Korean Sarcopenic Obesity Study (KSOS). Diabetes Care 2010; 33:1497-1499. Sarcopenia, measured by skeletal muscle index, was more prevalent in older men and women withT2DM compared with those with normal glycemic control.
71. Dominguez LJ, Barbagallo M. The cardiometabolic syndrome and sarcopenic obesity in older persons. J Cardiometab Syndr 2007; 2:183-189.
72. Baumgartner RN, Stauber PM, Koehler KM, et al. Associations of fat and muscle masses with bone mineral in elderly men and women. Am J Clin Nutr 1996; 63:365-372. (Pubitemid 26074697)
73. Reid IR, Plank LD, Evans MC. Fat mass is an important determinant of whole body bone density in premenopausal women but not in men. J Clin Endocrinol Metab 1992; 75:779-782.
74. Reid IR, Ames R, Evans MC, et al. Determinants of total body and regional bone mineral density in normal postmenopausal women: a key role for fat mass. J Clin Endocrinol Metab 1992; 75:45-51.
75. Zhao LJ, Jiang H, Papasian CJ, et al. Correlation of obesity and osteoporosis: effect of fat mass on the determination of osteoporosis. J Bone Miner Res 2008; 23:17-29.
76. Confavreux CB, Levine RL, Karsenty G. A paradigm of integrative physiology, the crosstalk between bone and energy metabolisms. Mol Cell Endocrinol 2009; 310:21-29.
77. Reseland JE, Syversen U, Bakke I, et al. Leptin is expressed in and secreted from primary cultures of human osteoblasts and promotes bone mineralization. J Bone Miner Res 2001; 16:1426-1433. (Pubitemid 32675194)
78. Thomas T, Gori F, Khosla S, et al. Leptin acts on human marrow stromal cells to enhance differentiation to osteoblasts and to inhibit differentiation to adipocytes. Endocrinology 1999; 140:1630-1638. (Pubitemid 29149231)
79. Jurimae J, Jurimae T, Leppik A, et al. The influence of ghrelin, adiponectin, and leptin on bone mineral density in healthy postmenopausal women. J Bone Miner Metab 2008; 26:618-623.
80. Jang M, Mistry A, Swick AG, et al. Leptin rapidly inhibits hypothalamic neuropeptide Y secretion and stimulates corticotropin-releasing hormone secretion in adrenalectomized mice. J Nutr 2000; 130:2813-2820.
81. Ducy P, Amling M, Takeda S, et al. Leptin inhibits bone formation through a hypothalamic relay: a central control of bone mass. Cell 2000; 100:197-207. (Pubitemid 30064908)
82. Kanazawa I, Yamaguchi T, Sugimoto T. Baseline serum total adiponectin level is positively associated with changes in bone mineral density after 1-year treatment of type 2 diabetes mellitus. Metabolism 2010; 59:1252-1256.
83. Kontogianni MD, Dafni UG, Routsias JG, et al. Blood leptin and adiponectin as possible mediators of the relation between fat mass and BMD in perimenopausal women. J Bone Miner Res 2004; 19:546-551. (Pubitemid 41071213)
84. Kanazawa I, Yamaguchi T, Yamamoto M, et al. Relationships between serum adiponectin levels versus bone mineral density, bone metabolic markers, and vertebral fractures in type 2 diabetes mellitus. Eur J Endocrinol 2009; 160:265-273.
85. Wang X, Shen X, Li X, et al. Age-related changes in the collagen network and toughness of bone. Bone 2002; 31:1-7. (Pubitemid 34754417)
86. Viguet-Carrin S, Roux JP, Arlot ME, et al. Contribution of the advanced glycation end product pentosidine and of maturation of type I collagen to compressive biomechanical properties of human lumbar vertebrae. Bone 2006; 39:1073-1079. (Pubitemid 44528385)
87. Saito M, Marumo K. Collagen cross-links as a determinant of bone quality: a possible explanation for bone fragility in aging, osteoporosis, and diabetes mellitus. Osteoporos Int 2010; 21:195-214. Collagen cross-link formation that occurs with age and T2DM may mediate bone fragility.
88. Schwartz AV, Garnero P, Hillier TA, et al. Pentosidine and increased fracture risk in older adults with type 2 diabetes. J Clin Endocrinol Metab 2009; 94:2380-2386.
89. Yamamoto M, Yamaguchi T, Yamauchi M, et al. Serum pentosidine levels are positively associated with the presence of vertebral fractures in postmenopausal women with type 2 diabetes. J Clin Endocrinol Metab 2008; 93:1013-1019. (Pubitemid 351398587)
90. Zhou S, Greenberger JS, Epperly MW, et al. Age-related intrinsic changes in human bone-marrow-derived mesenchymal stem cells and their differentiation to osteoblasts. Aging Cell 2008; 7:335-343. (Pubitemid 351663902)
91. Sethe S, Scutt A, Stolzing A. Aging of mesenchymal stem cells. Ageing Res Rev 2006; 5:91-116. (Pubitemid 43139669)
92. Conboy IM, Conboy MJ, Wagers AJ, et al. Rejuvenation of aged progenitor cells by exposure to a young systemic environment. Nature 2005; 433:760-764. (Pubitemid 40292986)
93. Ben David D, Reznick AZ, Srouji S, et al. Exposure to pro-inflammatory cytokines upregulates MMP-9 synthesis by mesenchymal stem cells-derived osteoprogenitors. Histochem Cell Biol 2008; 129:589-597.
94. Lacey DC, Simmons PJ, Graves SE, et al. Proinflammatory cytokines inhibit osteogenic differentiation from stem cells: implications for bone repair during inflammation. Osteoarthritis Cartilage 2009; 17:735-742.
95. Cramer C, Freisinger E, Jones RK, et al. Persistent High Glucose Concentrations Alter the Regenerative Potential of Mesenchymal Stem Cells. Stem Cells Dev 2010; 19:1875-1884. Adipose-derived mesenchymal stem cells demonstrated reduced osteogenic potential when taken from patientss with T2DM.
96. Kume S, Kato S, Yamagishi S, et al. Advanced glycation end-products attenuate human mesenchymal stem cells and prevent cognate differentiation into adipose tissue, cartilage, and bone. J Bone Miner Res 2005; 20:1647-1658. (Pubitemid 41243553)
97. Takagi M, Kasayama S, Yamamoto T, et al. Advanced glycation endproducts stimulate interleukin-6 production by human bone-derived cells. J Bone Miner Res 1997; 12:439-446. (Pubitemid 27120481)
98. Kassem M. Cellular and molecular effects of growth hormone and estrogen on human bone cells. APMIS Suppl 1997; 71:1-30.
99. Schwartz AV, Vittinghoff E, Bauer DC, et al. Association of BMD and FRAX score with risk of fracture in older adults with type 2 diabetes. JAMA 2011; 305:2184-2192.
100. Rauch F. Bone biopsy: indications and methods. Endocr Dev 2009; 16:49-57.
101. Brandi ML. Microarchitecture, the key to bone quality. Rheumatology (Oxford) 2009; 48 (Suppl 4):iv3-iv8.
102. Liu XS, Cohen A, Shane E, et al. Bone density, geometry, microstructure, and stiffness: Relationships between peripheral and central skeletal sites assessed by DXA, HR-pQCT, and cQCT in premenopausal women. J Bone Miner Res 2010; 25:2229-2238.
103. Cohen A, Dempster DW, Muller R, et al. Assessment of trabecular and cortical architecture and mechanical competence of bone by high-resolution peripheral computed tomography: comparison with transiliac bone biopsy. Osteoporos Int 2010; 21:263-273. There are few significant associations between measures of bone microarchitecture as determined by bone biopsy versus HR-pQCT.
104. Burghardt AJ, Issever AS, Schwartz AV, et al. High-Resolution Peripheral Quantitative Computed Tomographic Imaging of Cortical and Trabecular Bone Microarchitecture in Patients with Type 2 Diabetes Mellitus. J Clin Endocrinol Metab 2010; 95:5045-5055. First study to use HR-pQCT to compare bone microarchitecture in patients with and without T2DM.
105. Diez-Perez A, Guerri R, Nogues X, et al. Microindentation for in vivo measurement of bone tissue mechanical properties in humans. J Bone Miner Res 2010; 25:1877-1885. Description of microindentation, a novel and minimally-invasive technique for measuring bone toughness.
106. Yamaguchi T, Yamamoto M, Kanazawa I, et al. Quantitative ultrasound and vertebral fractures in patients with type 2 diabetes. J Bone Miner Metab 2011; 29:626-632.
107. Akin O, Gol K, Akturk M, et al. Evaluation of bone turnover in postmenopausal patients with type 2 diabetes mellitus using biochemical markers and bone mineral density measurements. Gynecol Endocrinol 2003; 17:19-29. (Pubitemid 36349878)
108. Gerdhem P, Isaksson A, Akesson K, et al. Increased bone density and decreased bone turnover, but no evident alteration of fracture susceptibility in elderly women with diabetes mellitus. Osteoporos Int 2005; 16:1506-1512. (Pubitemid 41790853)
109. Okazaki R, Totsuka Y, Hamano K, et al. Metabolic improvement of poorly controlled noninsulin-dependent diabetes mellitus decreases bone turnover. J Clin Endocrinol Metab 1997; 82:2915-2920. (Pubitemid 27385648)
110. Vestergaard P, Rejnmark L, Mosekilde L. Are antiresorptive drugs effective against fractures in patients with diabetes? Calcif Tissue Int 2011; 88:209-214.